Oxford BioTherapeutics (OBT) is a clinical-stage oncology company focused on next-generation immune-oncology (IO) therapies that recruit the immune system to recognise and attack cancer cells. The company operates two proprietary platforms: the OBT IO Discovery proteomics database and a library of tumour cultures for rapid testing. OBT works with global pharmaceutical companies and is already generating revenue through relationships with partners including The Menarini Group and Boehringer Ingelheim. It currently has two programmes in Phase I clinical trials—one in Acute Myeloid Leukaemia and another across breast, bladder and Non‑Hodgkin’s Lymphoma—run in collaboration with The Menarini Group. The company’s near-term plans include advancing its IO pre-clinical pipeline into clinical development and progressing additional therapeutic leads. OBT is headquartered in Abingdon, Oxfordshire. Oxford BioTherapeutics is a clinical-stage biotechnology company focused on developing antibody-based therapies to treat cancer. It combines immuno-oncology, antibody-drug conjugate (ADC) and human monoclonal antibody approaches against novel tumor cell membrane-derived checkpoint targets identified using its target selection and validation platform. Led by CEO Christian Rohlff, PhD, the company’s pipeline comprises 16 product candidates, including partnered and unpartnered programs. That pipeline includes MEN1112 (OBT357), a cell-mediated cytotoxicity antibody in a Phase I trial in acute myeloid leukemia, and MEN1309 (OBT076), an ADC for non-Hodgkin lymphoma, triple-negative metastatic breast cancer and other solid tumors. The company intends to use new financing to progress its immuno-oncology and ADC programs through development. Oxford BioTherapeutics is based in Abingdon, Oxfordshire, UK and San Jose, California. Oxford BioTherapeutics is an Oxon, UK-based international clinical-stage biotechnology company led by CEO Christian Rohlff. The company focuses on developing innovative antibody-based therapeutics, including antibody-drug conjugates (ADCs). It combines collaborations with other companies in the ADC field and its proprietary OGAP® target discovery system to provide a range of validated, novel antigen targets. The firm is advancing its research and development pipeline and is actively financing that expansion. To support those efforts, Oxford BioTherapeutics secured debt financing alongside equity to accelerate R&D. The company is using strategic financing to underwrite continued preclinical and clinical development activities.

Total raised

$23M

Funding rounds

3

Latest round

Equity

Latest activity

Aug 2018